期刊文献+

5-HT_3受体拮抗药研究概况 被引量:8

下载PDF
导出
摘要 恶性肿瘤化疗时胃肠道副反应引起的恶心、呕吐最为常见,大约占化疗病人的75%,这些不良反应降低了病人的生活质量,限制了用药疗程和剂量。近年来发现5-HT,受体拮抗药止吐疗效较为满意,并已发展为一类主要用于预防、治疗肿瘤的化疗和放疗诱发恶心、呕吐的新型药物。这类药物剂量小,止吐作用确切、毒副作用低,特别是没有多巴胺受体阻滞药常引起的严重锥体外系反应,被认为是“止吐疗法上的突破性的进步”。
作者 温悦 王丽婷
出处 《中国药师》 CAS 2006年第10期961-962,共2页 China Pharmacist
  • 相关文献

参考文献15

  • 1Favero AD,Roila F,Tonato M.Reducing chemotherapy induced nausea and vomiting(current perspective and future possibilities)[J].Drug Safety,1993,9(6):410-413
  • 2Wijingaarden IV,Tulp MTHM,Soudijin W.Serotoninagonists and antagoni-sts pharmacogical tools and therapertics[J].Recl Trav Chim Pays-Bas,1993,112-126
  • 3Gothert M.5-Hydroxytryptamine receptors.Arzneim.Forsch[J].Drug Res,1992,42(Ⅰ) (2a):238-243
  • 4袁静.5-HT_3受体拮抗剂抑制化疗致吐作用的评价[J].国外医学(药学分册),1998,25(5):279-282. 被引量:13
  • 5Tan M.Granisetron:new insights into its use for the treatment of chemother apyin-duced nausea and vomiting[J].expert opin pharmacother,2003,4(9):1563-1571
  • 6Thongprasert S.Efficacy and tolerability of tropisetron in the preven-tion of cisplatin-induced nausea and vomiting in advanced non-small cell lung cancer[J].Acta Oncol,2000,39,221-224
  • 7陈晓品,张菊,戴晓波,张玲,吴永忠,张涛,朱宇熹,甘露.托烷司琼对化疗治疗癌症防治呕吐的临床研究[J].中国药师,2004,7(7):551-553. 被引量:1
  • 8Kelley SP,Hodge CW.The 5-HT3 antagonist Y-25130 blocks cocaine-induc-ed lowering of ICSS reward thresholds in the rat[J].Pharmacol Biochem Behav,2003,74(2):297-302
  • 9Eisenberg P,Mackintosh FR,Ritch P,et al.Efficacy,safety and pharma-cokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study[J].Annals of Oncology,2004,15(2):330-337
  • 10Anonymous.Palonosetron(Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy[J].Med Lett Drugs Ther,2004,46(1179):28

二级参考文献20

  • 1王更利,尹绪德,姚文秀,傅彬玉,王谊.昂丹司琼和甲氧氯普胺在肿瘤化学疗法时作为止吐剂的对比[J].新药与临床,1994,13(6):350-352. 被引量:2
  • 2Farber L, Stratz TH, Bruckle W, et al. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients[J]. Int J Clin Pharmacol Res, 2001,21(1):1-13
  • 3Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists[J]. Scand J Rheumatol Suppl. 2000,113:37-45
  • 4Simpson K, Spencer CM, Mc Clellan KJ, et al. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting[J]. Drugs, 2000,59 (6):1297-1315
  • 5Chua DT, Sham JS, Kwong DL, et al. Comparative effcacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study[J]. Am J Clin Oncol. 2000,23 (2):185-191
  • 6Yokoyama T. Pharmacological review of tropisetron[J]. Nippon Yakurigaku Zasshi. 1999,114 (4): 219-226
  • 7RUBENSTEIN EB, GRALLA RJ, HAINSWORTH JD, et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy[J]. Cancer, 1997,79(4):1216-1224.
  • 8BLEIBERG HH, SPIELMANN M, FALKSON G, et al. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study[J]. Clin Ther, 1995,17(2):238-251.
  • 9ETTINGER DS, ELSENBERG PD, FITTS D, et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy[J]. Cancer, 1996,78(1):144-151.
  • 10BURRIS H, HESKETH P, COHN J, et al. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy[J]. Cancer J Sci Am, 1996,2(1):85-90.

共引文献17

同被引文献93

引证文献8

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部